Boehringer and Combotope partner for cancer antibodies
Pharmaceutical Business Review
The partnership will combine Combotope's SMART-Phage discovery platform with Boehringer Ingelheim's research and development capabilities, focusing on multiple identified oncology targets.
pharminent
June 24, 2026 (Last updated: June 24, 2026)
Pharmaceutical Business Review
The partnership will combine Combotope’s SMART-Phage discovery platform with Boehringer Ingelheim’s research and development capabilities, focusing on multiple identified oncology targets.